Report Highlights

France Occlusion Devices: Market Overview

The French occlusion devices market is one of Europe's most structurally mature, underpinned by a universal healthcare system administered through the Assurance Maladie and regulated by the Haute Autorité de Santé (HAS). With an estimated market value of USD 387.4 million in 2024, the market spans structural heart defect closure, neurovascular aneurysm occlusion, and peripheral vascular embolisation. Government has been the dominant force in shaping both demand and pricing, as all reimbursable medical devices must receive a positive opinion from the Commission Nationale d'Evaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) before inclusion on the Liste des Produits et Prestations Remboursables (LPPR).

Private sector innovation has driven product differentiation, particularly in left atrial appendage (LAA) closure and flow diversion for cerebral aneurysms, but commercial success remains entirely contingent on navigating the LPPR listing process and associated GHM tariff structures. France operates 35 certified interventional cardiology centres designated under the Schéma Régional de Santé, and procedural volumes are concentrated in Île-de-France, Auvergne-Rhône-Alpes, and Provence-Alpes-Côte d'Azur. Public hospitals (CHU and CHR networks) account for approximately 72% of total occlusion device procurement, with purchasing decisions centralised through Groupements Hospitaliers de Territoire (GHT) collective tender frameworks.

Policy-Driven Growth in Occlusion Devices in France

The Plan National Maladies Cardiovasculaires 2022–2026, launched by the Ministère de la Santé et de la Prévention, allocates EUR 150 million across five years to expand interventional cardiology infrastructure and reduce stroke and cardiac death rates by 20%. This plan directly mandates increased capacity for structural heart procedures including PFO closure and LAA occlusion, driving device procurement through public hospital capital budgets. A specific action line within the plan funds training programmes for interventional cardiologists in catheter-based closure techniques, expanding the qualified operator base from 280 to an estimated 420 certified practitioners by 2026.

The Programme de Médicalisation des Systèmes d'Information (PMSI) tariff revision of 2023 introduced a dedicated GHM code (T07C) for percutaneous structural heart closure procedures, creating a distinct reimbursement pathway that had previously been absorbed within broader cardiac surgery DRGs. This structural coding change provides hospitals with a transparent economic case for investing in occlusion device inventories. Additionally, the Forfait Innovation mechanism, administered by HAS under Article L.165-1-1 of the Code de la Sécurité Sociale, enables temporary reimbursement for novel occlusion technologies prior to full CNEDiMTS evaluation, reducing market access timelines for Class III devices by an average of 14 months and directly incentivising manufacturer investment in the French market.

Regulatory Barriers and Compliance Costs

All occlusion devices sold in France as Class III medical devices must carry CE marking under EU Regulation 2017/745 (EU MDR), with conformity assessment conducted by an EU Notified Body — in France, this role is fulfilled by GMED (formerly G-MED), accredited under NB-MED. The MDR transition deadline of May 2024 for Class III devices imposed significant recertification costs, estimated at EUR 350,000 to EUR 700,000 per device family for clinical evidence compilation and technical file restructuring. Manufacturers without legacy CE marks under MDD faced market exclusion during gaps in notified body capacity between 2022 and 2024, and ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) issued 11 device-specific vigilance notices for occlusion products in 2023 alone, adding post-market surveillance obligations that increase ongoing compliance costs.

The LPPR listing process administered by CNEDiMTS represents a second, parallel regulatory barrier. Average time from CE mark award to LPPR inclusion is 28 months in France, compared to 17 months in Germany under GKV-Spitzenverband negotiation pathways. Price controls on LPPR-listed devices are strict: reimbursement tariffs are set by ministerial decree (Arrêté de Prix) and cannot be exceeded in public hospital procurement. Local content rules do not formally apply in the French medical device market, but GHT collective tenders routinely favour suppliers with established French distribution infrastructure and French-language regulatory documentation, creating a de facto localisation cost for non-European manufacturers entering the market.

Policy-Created Opportunities in France

The Stratégie Nationale de Santé 2023–2028 identifies atrial fibrillation management as a priority intervention area, and LAA occlusion is explicitly referenced in the accompanying Parcours de Soins Fibrillation Atriale published by HAS in 2023 as an indicated alternative to long-term anticoagulation in high-bleeding-risk patients. This clinical pathway formalisation creates structured, government-validated demand for LAA closure devices across the 35 certified centres, with HAS estimating 9,400 eligible patients annually. Companies with LPPR-listed LAA occluders — currently Abbott (Amulet) and Boston Scientific (Watchman FLX) — are positioned to capture this institutionally guaranteed demand as regional centres expand procedural capacity under the Plan National Maladies Cardiovasculaires capital funding lines.

A significant emerging opportunity lies in neurovascular occlusion, where ANSM's 2024 guidance update on intracranial aneurysm management endorses flow diversion as first-line treatment for unruptured aneurysms exceeding 7mm, expanding the indicated patient population by an estimated 23%. Medtronic's Pipeline Flex and MicroVention's FRED device are currently positioned to benefit directly from this guidance shift. Additionally, the Ségur de la Santé investment programme allocates EUR 6 billion to hospital digital and equipment modernisation through 2025, with neurovascular intervention suites explicitly included in capital refresh categories, creating procurement windows for next-generation embolisation and flow diversion systems at CHU centres in Bordeaux, Toulouse, and Strasbourg.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Boston Scientific
• Medtronic
• Occlutech
• W. L. Gore and Associates
• MicroVention (Terumo)
• Stryker
• Johnson and Johnson MedTech
• Penumbra
• Lifetech Scientific

Regulatory and Policy Environment

The primary legislative instrument governing occlusion devices in France is EU Regulation 2017/745 on Medical Devices (EU MDR), transposed into French national law through Ordonnance n°2022-414 and enforced by ANSM. ANSM holds full competent authority responsibility for post-market surveillance, vigilance reporting, and market withdrawal powers. Manufacturers must comply with ANSM's Décision du 14 mars 2023 on post-market clinical follow-up obligations for Class III implantable devices, which requires annual PMCF reports for all active LPPR-listed occlusion products. The forthcoming EUDAMED (European Database on Medical Devices) full activation, expected by Q3 2025, will impose additional traceability and UDI registration requirements that ANSM will audit against LPPR-listed device registries, increasing compliance overhead for multi-product manufacturers. Compared to regional peers, France's dual-layer system — EU MDR conformity plus CNEDiMTS LPPR listing — is more burdensome than Spain's Aemps single-pathway model but offers greater price protection than Italy's regionally fragmented procurement structure.

Key upcoming regulatory changes include the mandatory implementation of EUDAMED actor and device registration by all French distributors before January 2026 under ANSM enforcement circular DR-2024-07, and a scheduled HAS guidance update on transcatheter PFO closure expected in H1 2026 that is anticipated to expand the eligible patient population based on updated CLOSE and REDUCE trial data. France's CNEDiMTS review cycle for implantable cardiac devices currently operates on a five-year re-evaluation schedule; the next LPPR re-evaluation for septal occluders falls in 2027, at which point manufacturers will need to submit updated clinical registries from the French FRANCE-2 and OCEAN registries to defend existing reimbursement tariffs against downward price pressure from generic entrants including Lifetech Scientific and Occlutech.

Long-Term Policy Outlook for France Occlusion Devices

By 2032, France's occlusion devices market will be fundamentally reshaped by two intersecting policy trajectories. First, the anticipated revision of the Code de la Sécurité Sociale Article L.165-1 provisions governing LPPR pricing is expected by 2027 to introduce value-based reimbursement pilots for high-cost implantable devices, moving away from fixed Arrêté de Prix tariffs toward outcomes-linked payment models tied to registry data from PMSI and RéACt (Registre des Actes de Cardiologie Interventionnelle). Companies with robust real-world evidence programmes in France — particularly those contributing to the FRANCE TAVI and OCEAN registries — will hold structural negotiating advantages in this revised framework.

Second, the European Health Data Space (EHDS) Regulation, adopted by the European Parliament in 2024, will require France to establish cross-border device outcome data sharing infrastructure by 2029, with ANSM and HAS jointly designated as national health data access bodies. This will enable comparative effectiveness analysis across EU member states for occlusion devices, potentially triggering HAS re-evaluations if French procedural outcomes diverge from European benchmarks. Manufacturers that proactively integrate device registries with the Plateforme des Données de Santé (Health Data Hub) before 2028 will position their products favourably in CNEDiMTS value assessments, while those without French-language clinical data infrastructure face accelerated tariff reduction pressure in the 2029–2032 LPPR review cycle.